UCM.AX Uscom Limited ASX closes A$0.012 09 Feb 2026: oversold bounce watch

At market close on 09 Feb 2026 the UCM.AX stock price finished at A$0.012, signalling a low-priced, low-liquidity setup that may suit an oversold bounce play. The stock shows a recent three‑month recovery of +9.09% after a six‑month fall of -52.00%, creating a short-term bounce case. We examine the technical triggers, fundamentals and a Meyka AI forecast to frame risk and potential entry points for traders and investors.

UCM.AX stock intraday snapshot and key numbers

Uscom Limited (UCM.AX) closed at A$0.012 on the ASX with volume 5,000.00 vs avgVolume 18,816.00. Day low and high were both A$0.012. Market cap is A$3,121,765.00 and shares outstanding are 260,147,083.00.

Shorter moving data shows 50‑day avg A$0.011 and 200‑day avg A$0.019. Year range is A$0.011–A$0.045. Reported EPS is -0.02 and PE reads -0.60, reflecting current losses.

UCM.AX stock technicals and the oversold bounce case

The technical setup supports an oversold bounce thesis for UCM.AX stock. Price sits just above the year low A$0.011, a short-term support zone. The 50‑day average near A$0.011 offers a nearby pivot while the 200‑day average at A$0.019 is the first meaningful resistance.

Liquidity is thin. Average volume is 18,816.00 and today’s volume was 5,000.00, so any reliable bounce should be confirmed by sustained volume above the 10‑day and 50‑day averages. Traders should wait for a clear close above A$0.015 with volume pickup.

UCM.AX stock fundamentals and valuation

Uscom operates in Healthcare, Medical – Devices, with small-scale revenue per share A$0.013 and negative net income per share -0.017. Cash per share is A$0.005 and the current ratio is 0.95, indicating tight liquidity. Price to sales is 1.21, while price to book shows negative values owing to reported equity deficits.

High payables and slow inventory turnover elevate working capital risk. Debt metrics are mixed, with enterprise value A$4,418,872.00 and net debt ratios that warrant caution for longer-horizon investors.

Meyka AI rates UCM.AX with a score out of 100

Meyka AI rates UCM.AX with a score of 61.81 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

The score reflects modest revenue growth and weak profitability. It flags liquidity and valuation risks, balanced by product IP and a low market capitalisation that makes sharp moves more likely in either direction.

UCM.AX stock catalysts, risks and sector context

Upcoming catalyst: Uscom has an earnings announcement scheduled for 25 Feb 2026. That report could set the next directional move for the UCM.AX stock. Sector peers in Healthcare show stronger averages, so comparative weakness may limit investor appetite.

Key risks include continued losses, thin trading liquidity and long inventory days. Strengths include specialised medical devices and distribution channels. Regulatory or tender wins would be material positive catalysts.

UCM.AX stock price forecast and practical targets

Meyka AI’s forecast model projects a short‑term yearly price of A$0.002 for UCM.AX. Compared with the current A$0.012, that implies an -83.33% downside under the model. Forecasts are model‑based projections and not guarantees.

For an oversold bounce strategy we set pragmatic targets: a conservative recovery target A$0.030 (upside 150.00%) and a near-term resistance target at the 200‑day average A$0.019. Tactical stop ideas include a close below A$0.011. Confirm any trade with rising volume above 18,816.00.

Sources: Investing.com UCM compare and Investing.com HitiQ comparison. Also see the company site for product details at Uscom.

Final Thoughts

UCM.AX stock closed A$0.012 on 09 Feb 2026, creating a classic oversold bounce setup for short-term traders. The price sits near the year low A$0.011 and the 50‑day average A$0.011 provides immediate support. Trade confirmation should require volume above 18,816.00 and a firm close above A$0.015. Meyka AI’s model projects A$0.002, implying downside risk of -83.33%, but model projections are not guarantees. For tactical plays, a measured entry with a tight stop near A$0.011 and targets at A$0.019 (first resistance) and A$0.030 (recovery target) suits the risk profile. Maintain position size discipline because of thin liquidity and elevated operational risk in the Healthcare devices sector. Meyka AI, as an AI‑powered market analysis platform, flags UCM.AX for high volatility and recommends confirming any move with volume and the upcoming earnings release on 25 Feb 2026.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.